European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. https://doi.org/10.1016/j.jhep.2024.04.031.

Article  CAS  Google Scholar 

Boeckmans J, Hagstrom H, Cryer DR, Schattenberg JM. The importance of patient engagement in the multimodal treatment of MASLD. Commun Med. 2025;5(1):148. https://doi.org/10.1038/s43856-025-00871-1.

Article  PubMed  PubMed Central  Google Scholar 

Adinolfi LE, Marrone A, Rinaldi L, Nevola R, Izzi A, Sasso FC. Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management. Explor Med. 2025;6:1001281.

Article  CAS  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56. https://doi.org/10.1016/j.jhep.2023.06.003.

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. https://doi.org/10.1097/HEP.0000000000000004.

Article  PubMed  PubMed Central  Google Scholar 

Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, et al. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024;158:155958. https://doi.org/10.1016/j.metabol.2024.155958.

Article  CAS  PubMed  Google Scholar 

Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol Diabetes Metab. 2025;8(6):e70132. https://doi.org/10.1002/edm2.70132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–48. https://doi.org/10.1136/gutjnl-2023-330110.

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010 e8. https://doi.org/10.1016/j.cgh.2024.03.006.

Article  PubMed  Google Scholar 

Platek AE, Szymanska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Exp Hepatol. 2023;9(3):187–92. https://doi.org/10.5114/ceh.2023.130744.

Article  PubMed  PubMed Central  Google Scholar 

Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;31(Suppl):S32-50. https://doi.org/10.3350/cmh.2024.0431.

Article  PubMed  PubMed Central  Google Scholar 

Li Z, Li Z, Cao D, Hu Y. Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world. J Hepatol. 2025;82(1):e29–31. https://doi.org/10.1016/j.jhep.2024.09.027.

Article  PubMed  Google Scholar 

Hashida R, Nakano D, Kawaguchi M, Younossi ZM, Kawaguchi T. Changing from NAFLD to MASLD: the implications for health-related quality of life data. J Hepatol. 2024;80(6):e249-51. https://doi.org/10.1016/j.jhep.2024.02.010.

Article  PubMed  Google Scholar 

Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82(2):487–503. https://doi.org/10.1097/hep.0000000000000735.

Article  PubMed  Google Scholar 

Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134–48. https://doi.org/10.1016/S2213-8587(24)00318-8.

Article  CAS  PubMed  Google Scholar 

Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7(3):101271. https://doi.org/10.1016/j.jhepr.2024.101271.

Article  PubMed  Google Scholar 

Danpanichkul P, Suparan K, Diaz LA, Fallon MB, Chen VL, Namsathimaphorn K, et al. The rising global burden of MASLD and other metabolic diseases (2000–2021). United Eur Gastroenterol J. 2025;13(7):1141–54. https://doi.org/10.1002/ueg2.70072.

Article  Google Scholar 

Younossi ZM, Mangla KK, Chandramouli AS, Lazarus JV. Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. Hepatol Commun. 2024;8(8):e0488. https://doi.org/10.1097/HC9.0000000000000488.

Article  PubMed  PubMed Central  Google Scholar 

Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML, et al. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutr Metab Cardiovasc Dis. 2020;30(6):1014–22. https://doi.org/10.1016/j.numecd.2020.02.016.

Article  PubMed  Google Scholar 

Torre E, Di Matteo S, Martinotti C, Bruno GM, Goglia U, Testino G, et al. Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives. Clinicoecon Outcomes Res. 2024;16:773–84. https://doi.org/10.2147/ceor.S472446.

Article  PubMed  PubMed Central  Google Scholar 

Sanai FM, Al Khathlan A, Al Fadhli A, Jazzar AS, Hashim AM, Mansour E, et al. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. Hepatol Int. 2021;15(4):912–21. https://doi.org/10.1007/s12072-021-10182-x.

Article  PubMed  PubMed Central  Google Scholar 

Lu F, Liu J, She B, Yang H, Ji F, Zhang L. Global trends and inequalities of liver complications related to metabolic dysfunction-associated steatotic liver disease: an analysis from 1990 to 2021. Liver Int. 2025;45(4):e16120. https://doi.org/10.1111/liv.16120.

Article  PubMed  Google Scholar 

Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gomez M, et al. A European survey to identify challenges in the management of metabolic dysfunction-associated steatotic liver disease. Liver Int. 2025;45(2):e16224. https://doi.org/10.1111/liv.16224.

Article  PubMed  PubMed Central  Google Scholar 

Driessen S, de Jong VD, van Son KC, Klompenhouwer T, Colardelle Y, Alings M, et al. A global survey of health care workers’ awareness of non-alcoholic fatty liver disease: the AwareNASH survey. United Eur Gastroenterol J. 2023;11(7):654–62. https://doi.org/10.1002/ueg2.12445.

Article  Google Scholar 

Lee JH, Yoon EL, Oh JH, Kim K, Ahn SB, Jun DW. Barriers to care linkage and educational impact on unnecessary MASLD referrals. Front Med (Lausanne). 2024;11:1407389. https://doi.org/10.3389/fmed.2024.1407389.

Article  PubMed  PubMed Central  Google Scholar 

Noureddin M. Utilization of noninvasive tests to diagnose at-risk metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2023;19(9):568–70.

PubMed  PubMed Central  Google Scholar 

El-Kassas M, AlNaamani KM, Khalifa R, Yilmaz Y, Labidi A, Almattooq M, et al. Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa countries: insights into guidelines, infrastructure, and referral systems. J Clin Transl Hepatol. 2025;13(10):791–808. https://doi.org/10.14218/JCTH.2025.00286.

Article  PubMed  PubMed Central  Google Scholar 

Allen AM, Lazarus JV, Alkhouri N, Noureddin M, Wong VW, Tsochatzis EA, et al. Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2025;9(5). https://doi.org/10.1097/HC9.0000000000000678.

Article  PubMed  PubMed Central  Google Scholar 

American Association for the Study of Liver Diseases. New MASLD nomenclature 2023. Available from: https://www.aasld.org/new-masld-nomenclature. [Cited 2025 Dec].

Acierno C, Nevola R, Barletta F, Zielińska K, Rinaldi L, Sasso FC, et al. The transition from NAFLD to MASLD: implications for diagnosis, prognosis, and clinical management. Exploration of Medicine. 2025;6:1001365.